Tuesday's Health Winners & Losers

Cytokinetics ( CYTK) said its experimental head-and-neck cancer drug ispinesib failed a clinical trial in which it was meant to reduce or eliminate tumors. Cytokinetics shares were losing 14 cents, or 2.2%, to $6.21.

Allos Therapeutics ( ALTH) rose after the company said the Food and Drug Administration granted its lymphoma drug PDX fast-track review status. The stock was up 4% to $3.89.

Baxter International ( BAX) is selling its transfusion business for $540 million to a group that includes private equity firm Texas Pacific. Shares of Baxter were up 6 cents at $45.24.

Heart-device makers' stocks were mixed after Merrill Lynch medical technology analyst Katherine Owen issued a number of ratings changes. The analyst downgraded Abbott ( ABT) to neutral and Boston Scientific ( BSX) to sell. She reiterated her buy rating on Johnson & Johnson ( JNJ).

St. Jude Medical ( STJ), which separately announced that its chronic-pain neurostimulation system received regulatory and reimbursement approval in Australia, was upgraded to buy. Abbott's shares lost 1.3% to $47.61, Boston Scientific was 1.2% lower, trading at $14.50, St. Jude's stock gained 3% to $36.45, and J&J's shares were up 0.3% to $65.29.

Other health stocks on the move included Amgen ( AMGN), 1.4% higher to $71.26, Elan ( ELN), up 1.5% to $15.45, MGI Pharma ( MOGN) gaining 2.5% to $17.36, Meridian Bioscience ( VIVO) rising 4.9% to $23.59, SkyePharma ( SKYE), whose shares were boosted 10.4% to $5, and ViaCell ( VIAC), up 4.5% to $4.55.

Barr Pharmaceuticals ( BRL) lost 1.5% to $51.37, Novogen ( NVGN) traded 5.8% lower to $10.37, BioCryst Pharmaceuticals ( BCRX) fell 4.1% to $11.11, Valera Pharmaceuticals ( VLRX) lost 6.1% to $6.30, and Dyadic International ( DIL) shares were off 6.5% to $3.73.

More from Investing

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

Immigration, Instagram and Oil - Here's What You Can't Miss Wednesday

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes